Takeda to Divest TachoSil to Corza Health for ~$416M

 Takeda to Divest TachoSil to Corza Health for ~$416M

Takeda to Divest TachoSil to Corza Health for ~$416M

Shots:

  • Corza Health to acquire the assets and licenses supporting the development and commercialization of TachoSil while Takeda will retain its ownership of the manufacturing facility in Linz and Austria. The agreement is expected to be close by Mar 31, 2021
  • In May’2019, Takeda and Ethicon collaborated for the sales of TachoSil. The two companies mutually terminate the transaction in Apr’2020 because of anti-trust concerns raised by the EC
  • TachoSil is a surgical patch trusted by medical professionals globally to deliver safe, fast and reliable bleeding control

Click here ­to­ read full press release/ article | Ref: Takeda | Image: The Malaysian Reserve

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post